References

  1. Dorlands’s Illustrated Medical Dictionary, 30th Edition; 2003 by Elsevier.
  2. Gluckman E, Rocha V, Boyer-Chammard A, et al. Outcome of cord-blood transplantation from related and unrelated donors. N Engl J Med. 1997;337(6):373-381.
  3. Rocha V, Wagner J, Sobocinksi K, et al. Graft-Versus-Host Disease in children who have received a cord blood or bone marrow transplant from an HLA-Identical sibling. 2002;342(25):1846-1854.
  4. National Institutes of Health. Stem cell basics: 1. Introduction. http://stemcells.nih.gov. Accessed June 17, 2013.
  5. Schmit-Pokorny K. Expanding indications for stem cell transplantation. Semin Oncol Nurs. 2009;25(2):105-114.
  6. Moskowitz AJ, Moskowitz CH. Controversies in the treatment of lymphoma with autologous transplantation. Oncologist. 2009;14(9):921-929.
  7. Gratwohl A, Heim D. Current role of stem cell transplantation in chronic myeloid leukemia. Best Pract Res Clin Haematol. 2009;22(3):431-443.
  8. Minnema MC, van der Spek E, van der Donk NW, Lokhorst HM. New developments in the treatment of patients with multiple myeloma. Neth J Med. 2010;68(1):24-32.
  9. Chen Y-B, Hochberg EP, Feng Y, et al. Characteristics and outcomes after autologous stem cell transplants for patients with relapsed or refractory diffuse large B-cell lymphoma who failed initial rituximab, cyclophosphamide, adriamycin, vincristine, and prednisone therapy compared to patients who failed cyclophosphamide, adriamycin, vincristine, and prednisone. Leuk Lymphoma. 2010;51(5):789-796.
  10. The Leukemia & Lymphoma Society. Cord blood stem cell transplantation. No. 2. http://www.lls.org. Accessed June 17, 2013.
  11. St. Jude Children’s Research Hospital. Diseases treated by stem cell transplant.
    http://www.stjude.org. Accessed April 25, 2011.
  12. Rocha V, Gluckman E. Improving outcomes of cord blood transplantation: HLA matching, cell dose and other graft- and transplantation-related factors. British Journal of Hematology. 2009; 147:262-274.
  13. The National Marrow Donor Program. Trends in Allogeneic Transplants: NMDP Transplants by Cell Source (bone marrow, peripheral blood stem cells or cord blood), 1988-2010. http://www.marrow.org. Accessed May 9, 2011.
  14. The Leukemia & Lymphoma Society. Facts 2010-2011. http://www.lls.org. Accessed June 17, 2013.
  15. Harris DT. Non-haematological uses of cord blood stem cells. Br J Haematol. 2009;147(2):177-184.
  16. Seattle Cancer Care Alliance. Description of HLA. http://www.seattlecca.org/. Accessed April 25, 2011.
  17. The Bone Marrow Foundation. Become a bone marrow/stem cell donor. http://www.bonemarrow.org. Accessed June 17, 2013.
  18. Kamani N, Spellman S, Hurley CK, et al. State of the art review: HLA matching and outcome of unrelated donor umbilical cord blood transplants. Biol Blood Marrow Transplant. 2008;14:1-6.
  19. Gluckman E, Rocha V. Donor selection for unrelated cord blood transplants. Curr Opin Immunol. 2006;18(5):565-570.
  20. Schoemans H, Theunissen K, Maertens J, Boogaerts M, Verfaillie C, Wagner J. Adult umbilical cord blood transplantation: a comprehensive review. Bone Marrow Transplant. 2006:38(2):83-93.
  21. Data on file A, LifebankUSA; 2010.
  22. Data on file B, LifebankUSA; 2010.
  23. Wagner JE, Barker JN, DeFor TE, et al. Transplantation of unrelated donor umbilical cord blood in 102 patients with malignant and nonmalignant diseases: influence of CD34 cell dose and HLA disparity on treatment-related mortality and survival. Blood. 2002;100(5):1611-1618.
  24. Styczynski J, Cheung Y-K, Garvin J, et al. Unrelated donor transplants: outcomes of unrelated cord blood transplantation in pediatric recipients. Bone Marrow Transplant. 2004;34:129-136.
  25. Data on file C, LifebankUSA; 2010.
  26. Richardson SM, Hoyland JA, Mobasheri R, Csaki C, Shakibaei M, Mobasheri A. Mesenchymal stem cells in regenerative medicine: opportunities and challenges for articular cartilage and intervertebral disc tissue engineering. J Cell Physiol. 2010;222(1):23-32.
  27. Yen BL, Huang H-I, Chien C-C, et al. Isolation of multipotent cells from human term placenta. Stem Cells. 2005;23(1):3-9.
  28. Undale AH, Westendorf JJ, Yaszemski MJ, Khosla S. Mesenchymal Stem Cells for Bone Repair and Metabolic Bone Diseases. Mayo Clin Proc. 2009;84(10):893-902.
  29. Data on file D, LifebankUSA; 2010.
  30. Biosafe. Protocols for adult stem cell banking. http://biosafe.ch. Accessed June 17, 2013.
  31. Dobrila L, Chapman J, Marr D, Kumar V, Coelho P, Rubinstein P. ThermoGenesis AXP AutoXpress platform and BioArchive system for automated cord blood banking. ThermoGenesis Corp, Rancho Cordova, CA. 2006.
  32. Regan D, Wofford J, Wall D. Comparison of cord blood thawing methods on cell recovery, potency, and infusion. Transfusion. 2010:50:2670-2675.
  33. US Department of Health and Human Services, Food and Drug Administration, Center for Biologics Evaluation and Research. Guidance for industry: minimally manipulated, unrelated allogeneic placental/umbilical cord blood intended for hematopoietic reconstitution for specified indications. October 2009. http://www.fda.gov. Accessed April 23, 2011
  34. US Department of Health and Human Services. Bone marrow and cord blood donation and transplantation. http://bloodcell.transplant.hrsa.gov/. Accessed April 23, 2011.
  35. Kraus M, Foster K, Bridges AR, Walters MC. Cord blood units collected with liquid CPD appear to contain significantly more nucleated and CD34+ cells than units collected with dry heparin [abstract]. Blood (ASH Annual Meeting Abstracts). 2009;114. Abstract 4227. http://abstracts.hematologylibrary.org/cgi/content/abstract/114/22/4227. Accessed April 23, 2011.
  36. Mason C, Dunnill P. A brief definition of regenerative medicine. Regen Med. 2008;3(1):1-5.
  37. US Department of Health and Human Services. 2020: a new vision-a future for regenerative medicine. http://medicine.osu.edu/…2020vision.pdf. Accessed June 17, 2013.
  38. Harris DT. Cord blood stem cells: a review of potential neurological applications. Stem Cell Rev. 2008;4(4):269-274
  39. Harris DT, Badowski M, Ahmad N, et al. The potential of cord blood stem cells for use in regenerative medicine. Expert Opin Biol Ther. 2007;7(9):1311–1322.
  40. Jazedje T, Secco M, Vieira NM, et al. Stem cells from umbilical cord blood do have myogenic potential, with and without differentiation induction in vitro. J Transl Med. 2009;7:6.
  41. Shyu MK, Yuan RH, Shih JC, et al. Kinetics and functional assay of liver repopulation after human cord blood transplantation. Dig Liver Dis. 2007;39(5);455-456.
  42. Dasari VR, Spomar DG, Li L, Gujrati M, Rao JS, Dinh DH. Umbilical cord blood stem cell mediated downregulation of Fas improves functional recovery of rats after spinal cord injury. Neurochem Res. 2008;33(1):134-149.
  43. Henning RJ, Aufman J, Shariff M, et al. Human umbilical cord blood mononuclear cells decrease fibrosis and increase cardiac function in cardiomyopathy. Regen Med. 2010;5(1):45-54.
  44. da Silva Meirelles L, Caplan AI, Nardi NB. In search of the in vivo identity of mesenchymal stem cells. Stem Cells. 2008;26(9):2287-2299.
  45. Nietfeld JJ, Pasquini MC, Logan BR, Verter F, Horowitz MM. Lifetime probabilities of hematopoietic stem cell transplantation in the U.S. Biol Blood Marrow Transplant. 2008;14(3):316-322.